AlloDx Multi-site DNA Methylation Model for Predicting SRNS Selected for a Poster at ASN 2024

Recently, research results of AlloDx's R&D team on 'multiplex methylation-site model for predicting SRNS' were invited to the American Society of Nephrology Annual Meeting—an academically influential renal society meeting in the global nephrology field—and will be presented as posters in the ASN 2024 Poster Session and Top Trainee Poster Session respectively.

Glucocorticoids are the first-line treatment for patients with nephrotic syndrome (NS). Approximately 20% of patients with nephrotic syndrome present with steroid-resistant nephrotic syndrome (SRNS). If SRNS can be identified before initial treatment, the potential side effects associated with subsequent steroid use can be reduced by using alternative immunosuppressants. Through research, the AlloDx R&D team discovered and confirmed the correlation between gene methylation changes and SRNS. At the same time, by detecting multiple CpG sites of specific genes, they established a model that can predict SRNS and achieved good AUC values ​​in both the training set and the validation set. The company's head of R&D said that with the further development and improvement of this research, it is expected to be transformed into a practical tool in clinical practice to improve and enhance the prognosis of SRNS patients.

The American Society of Nephrology (ASN) is a leading international professional society dedicated to kidney disease research, founded in 1966, and has over 21,240 members in 132 countries and regions worldwide to date. The ASN Annual Meeting held each year is a large-scale, high-level industry event in the global nephrology field. This year's ASN will be held from October 23 to 27, 2024 in San Diego, California, USA, and is expected to attract more than 12,000 nephrology experts, researchers, and healthcare industry professionals from around the world.

Regarding the selection of this poster, the relevant person in charge of AlloDx said that it is a great honor to bring this research to the international stage, and hopes that through this display, it can be shared with global peers and jointly promote the development of this field. In addition, the company will continue to explore other diagnostic and predictive models based on molecular markers to support the diagnosis and management of more types of kidney diseases to fulfill its corporate mission of improving patients' quality of life.